ATC
VIRX

Adirondack Trust Company’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Adirondack Trust Company’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5
Closed -$5K – 305
2013
Q3 		$5K Hold
5
– – ﹤0.01% 258
2013
Q2 		$5K Buy
+5
New +$5.57K ﹤0.01% 265

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Adirondack Trust Company's VIRX Position: Q4 2013 in Review

Adirondack Trust Company sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2013, closing a stake of 5 shares — an estimated $5K sold.

Adirondack Trust Company first reported a position in VIRX in Q2 2013 and held it in 2 quarters. The position peaked at $5K in Q3 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q4 2013.

  • Adirondack Trust Company reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Adirondack Trust Company sold 5 Viracta Therapeutics, Inc. Common Stock shares in Q4 2013, an estimated $5K.
  • Adirondack Trust Company first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Adirondack Trust Company's Viracta Therapeutics, Inc. Common Stock position peaked at $5K in Q3 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2013.

Based on Adirondack Trust Company's 13F filing for Q4 2013, filed 7 Jan 2014.